Welcome to our dedicated page for Filana Therapeutics news (Ticker: FLNA), a resource for investors and traders seeking the latest updates and insights on Filana Therapeutics stock.
Filana Therapeutics reports news centered on its TSC-related epilepsy development program, simufilam, and the company’s transition from Cassava Sciences to the FLNA corporate identity. Recurring updates include financial results, business updates, scientific presentations, preclinical publications, and regulatory commentary related to the program’s FDA clinical hold.
Company news also covers the biological rationale for modulating filamin A, preclinical work in TSC-related epilepsy models, and corporate developments tied to governance, reporting, and Nasdaq trading under the FLNA symbol.
Filana Therapeutics (NASDAQ: FLNA) reported Q1 2026 results and a business update on simufilam for TSC-related epilepsy on May 7, 2026. Cash was $86.6M at March 31, 2026; estimated cash at June 30, 2026 is $47–$50M. Net loss was $10.3M ($0.21/share); R&D and G&A declined year-over-year.
The company is addressing the FDA clinical hold with additional preclinical data and protocol changes and presented preclinical simufilam data at Eilat XVIII and in Epilepsia.
Filana Therapeutics (NASDAQ: FLNA) presented its biological rationale for evaluating simufilam in TSC-related epilepsy at Eilat XVIII in Madrid on May 5, 2026. The presentation covered the scientific and clinical rationale for the company’s program. Management said it is focused on addressing the clinical hold and will provide updates as available.
Filana Therapeutics (NASDAQ: FLNA) announced publication in Epilepsia (online Apr 14, 2026) of preclinical data showing that oral simufilam dose‑dependently attenuated seizure progression in the Tsc1‑cKO mouse, a severe model of TSC‑related epilepsy. The study reported a statistically significant correlation between dose and seizure counts and supports continued evaluation while the company works to resolve an FDA clinical hold.
Filana Therapeutics (NASDAQ: FLNA) reported 2025 results and a business update focused on its TSC-related epilepsy program and capital efficiency.
The company posted a net loss of $91.0 million ($1.88 per share) for 2025, year-end cash of $95.5 million and estimates cash of $47–$50 million at June 30, 2026. Filana is addressing FDA requests tied to a December 2025 clinical hold and expects to submit a response as soon as practicable.
Filana Therapeutics (NASDAQ: FLNA) is the new corporate name formerly known as Cassava Sciences, effective March 11, 2026.
The rebranding aligns the company with its strategic focus on developing medicines that modulate the filamin A protein to address CNS disorders, including Tuberous Sclerosis Complex-related epilepsy. The updated website is available at https://www.filanatx.com.